Cardima dispute headed to panel
This article was originally published in The Gray Sheet
Executive Summary
FDA's Medical Device Dispute Resolution Panel will convene April 19 in Gaithersburg, Md., to hear Cardima's arguments for PMA approval of its Revelation Tx atrial fibrillation device. An advisory panel voted unanimously to reject the application in 2003, citing study design problems (1"The Gray Sheet" June 2, 2003, p. 3). A dispute is eligible for review by the panel only if the matter is based on "sound scientific grounds," and if "sufficient effort" has been made to resolve the complaint through less formal mechanisms...
You may also be interested in...
Cardima’s Revelation: AF Self-Monitoring, Hazy Endpoints Hamper Review
The ability of self-reporting to accurately track reduction in atrial fibrillation burden is cast into doubt by FDA panel experience with Cardima's Revelation ablation system data submission
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.